Yüksel Ürün, Professor of Medical Oncology at Ankara University School of Medicine, shared on X:
“The first-line question in metastatic urothelial cancer is becoming easier. The second-line question is getting harder.
EV + pembrolizumab, if available, changed the algorithm. Now we need to define what comes next.”
You can also read: ‘Metastatic Renal Cell Carcinoma in 2026: Frontline Combinations, Post-IO Sequencing, and the Emergence of HIF-2α Inhibition‘
